发明名称 |
USE OF CCI-779 AS ANTINEOPLASTIC AGENT |
摘要 |
PROBLEM TO BE SOLVED: To provide the use of CCI-779 as an antineoplastic agent, and particularly for neoplasms which are refractory to standard therapy, or for patients for whom standard therapy is not appropriate.SOLUTION: The present invention provides pharmaceutical compositions containing rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) for use in treatment of refractory renal cell cancer in a mammal in which a neoplasm progressed following treatment with standard chemotherapy appropriate for the neoplasm.SELECTED DRAWING: None |
申请公布号 |
JP2016094444(A) |
申请公布日期 |
2016.05.26 |
申请号 |
JP20150241449 |
申请日期 |
2015.12.10 |
申请人 |
WYETH LLC |
发明人 |
DUKART GARY;GIBBONS JAMES JOSEPH JR;SPEICHER LISA ANNE;FROST PHILIP;DISCAFANI-MARRO CAROLYN MARY |
分类号 |
A61K31/436;C07D498/18;A61P13/12;A61P35/00 |
主分类号 |
A61K31/436 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|